Articles tagged with Protein Dimers
Researchers characterized the structure and function of a protein that regulates sugar and fat levels, finding it can work with an unexpected partner - itself. This partnership may drive the expression of different genes than its usual partner, offering new therapeutic targets for diseases like liver cancer and diabetes.
A new technique has been developed to study interactions between drugs and ion channels, allowing for faster and more economical design of targeted therapies. The method has been tested on P2X7 receptors, which are therapeutic targets for depression, autism spectrum disorders, and certain types of cancer.
Researchers found that HNL Dimer levels decrease rapidly within a day of successful antibiotic treatment, offering a time-saving advantage over traditional biomarkers. This study confirms the previous promising results and provides valuable insights for early diagnosis and treatment of sepsis.
Researchers discover that PD-1 forms dimers to function optimally, and manipulating its dimerization can enhance or inhibit T cell activity. This finding offers new insights into developing more effective cancer immunotherapies and treatments for autoimmune diseases.
Researchers at Johannes Gutenberg University Mainz discovered a unique cryptochrome protein in marine bristle worms that distinguishes between sunlight and moonlight. The protein's structure reveals an unusual light-induced change from dimer to monomer arrangements, allowing it to synchronize reproduction with lunar phases.
Researchers discovered a unique protein in bristle worms that distinguishes between sunlight and moonlight. The protein, L-Cry, disassembles under intense light and forms a stable connection in the dark.
A protein found in bacteria activates its enzymatic activity by up to 10,000 times when exposed to blue light, acting like an on-off switch. This discovery could lead to enhanced and optimized optogenetic tools and medical treatments.
Researchers found that BUB1 protein regulates EGFR signaling by reducing receptor internalization, which may lead to new therapeutic interventions for EGFR-driven cancers. The study also showed that BUB1 impacts receptor recycling and degradation, affecting signaling amplitude and duration.
Researchers designed artificial peptides that can bind to viral proteins, blocking entry into cells and causing viruses to clump together. These 'miniproteins' were found to be thermostable and safe for use in humans, with promising results in lab tests and animal models.
Researchers have developed a specialized technique to capture unique protein structures associated with neuropathy disorders, such as Charcot Marie Tooth and Dejerine-Sottas syndrome. The technique, ion mobility-mass spectrometry (IM-MS), reveals that an unstable mutant version of the PMP22 protein forms a stable complex called a dimer.